AUS
NZ
UK
CA
USA
IND
Evotec SE (NASDAQ: EVO) has announced a significant leap forward in its neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY), marking a milestone achievement in the quest for novel treatments for neurodegenerative diseases. The latest scientific breakthrough has triggered a research payment of US$20 million to Evotec, underscoring the fruitful partnership's dedication to advancing therapeutic innovation.
Since its inception in December 2016, the strategic collaboration between Evotec and Bristol Myers Squibb has been focused on identifying disease-modifying treatments for a wide spectrum of neurodegenerative disorders. With currently approved drugs offering only short-term symptom management, there exists a pressing need for therapeutic interventions capable of slowing down or halting disease progression, addressing the significant unmet medical needs in this field.
The partnership has yielded promising results, with a target-based program now progressing into late pre-clinical development. This advancement not only underscores the partnership's commitment to scientific excellence but also contributes to the rapid expansion of a robust pipeline spanning from discovery to clinical-stage programs in neurodegeneration.
One of the notable successes of the collaboration is the development of EVT8683, subsequently licensed by Bristol Myers Squibb as BMS-986419 in September 2021. Following a successful Phase I study, Bristol Myers Squibb announced plans for a Phase II trial scheduled to commence in 2024. This progression signifies a significant step forward in the clinical development of potential treatments for neurodegenerative diseases.
In March 2023, Bristol Myers Squibb and Evotec reaffirmed their commitment to collaboration by extending and expanding their partnership for an additional eight years. This strategic move underscores both companies' shared vision and dedication to addressing the complex challenges posed by neurological disorders.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, expressed enthusiasm for the partnership's continued success, stating, "We are excited to further expand our pipeline with another high-potential program progressing into late pre-clinical development, demonstrating the exceptional productivity of our neuroscience partnership with Bristol Myers Squibb and our shared commitment to innovation and patient care."
The collaborative efforts of Evotec and Bristol Myers Squibb have led to the advancement of a growing portfolio of programs, bringing them closer to the shared goal of delivering innovative therapeutic options for patients suffering from devastating neurological disorders. This latest scientific progress not only reinforces the companies' commitment to addressing unmet medical needs but also underscores their role as leaders in neuroscience innovation.
